Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 09:14 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the...
December 17, 2025 11:13 ET | Source: Janssen Cilag International NV

Beispiellose Ergebnisse der Phase III Studie MajesTEC-3 sprechen für TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) in subkutaner Formulierung als potenzieller Behandlungsstandard bereits in der Zweitlinienbehandlung für Patienten mit rezidiviertem/refraktärem multiplem Myelom

Die subkutane (SC) Kombination von teclistamab und daratumumab führte nach dreijähriger Nachbeobachtungszeit zu einem statistisch signifikanten Vorteil hinsichtlich des progressionsfreien Überlebens...
December 10, 2025 11:37 ET | Source: Janssen Cilag International NV

Une utilisation précoce de CARVYKTI®▼ (ciltacabtagène autoleucel) a permis d’obtenir des rémissions durables sans traitement pendant 2,5 ans chez des patients atteints d’un myélome multiple en rechute ou réfractaire

Les données de suivi issues de l’étude CARTITUDE-4 révèlent qu’au moins 80 pour cent des patients à risque standard traités n’ont présenté aucune progression de la maladie et n’ont reçu aucun...
December 09, 2025 09:21 ET | Source: Janssen Cilag International NV

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years...
December 08, 2025 11:18 ET | Source: Janssen Cilag International NV

Die frühere Anwendung von CARVYKTI®▼ (ciltacabtagene autoleucel) führte bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom nach 2,5 Jahren zu einer anhaltenden, behandlungsfreien Remission

Die Follow-up-Daten der CARTITUDE-4-Studie zeigen, dass mindestens 80 Prozent der tatsächlich behandelten Patienten mit Standardrisiko bereits nach einer einmaligen Infusion als Zweitlinientherapie...
December 06, 2025 09:30 ET | Source: Janssen Cilag International NV

Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data...
December 01, 2025 08:19 ET | Source: Janssen Cilag International NV

Johnson & Johnson ottiene l’approvazione della Commissione Europea per IMAAVY®▼ (nipocalimab), un nuovo bloccante FcRn che offre un controllo sostenuto della malattia in un’ampia popolazione di persone affette da miastenia gravis generalizzata (gMG)

Nipocalimab è il primo inibitore FcRn approvato per pazienti adulti e adolescenti affetti da gMG di età pari o superiore a 12 anni, che risultano positivi agli anticorpi anti-AChR o anti-MuSKNegli...
December 01, 2025 08:18 ET | Source: Janssen Cilag International NV

Johnson & Johnson receives European Commission approval of IMAAVY®▼ (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positiveIn the pivotal Phase 3 Vivacity-MG3 and Phase...
October 24, 2025 08:02 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous...
October 21, 2025 06:12 ET | Source: Janssen Cilag International NV

RYBREVANT®▼ par voie sous-cutanée (amivantamab) offre un taux de réponse global prometteur de 45 pour cent associé à une durée de réponse médiane de 7,2 mois dans le cancer de la tête et du cou récurrent ou métastatique

Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité...